Verastem reports 86% 6-month OS rate in RAMP 205 pancreatic cancer trial

Verastem Oncology announced positive updated results from RAMP 205 evaluating avutometinib plus defactinib combined with standard chemotherapy in first-line metastatic pancreatic cancer, showing an 86% overall survival rate at 6 months and 52% objective response rate. The encouraging efficacy data with manageable safety profile supports further development of the combination therapy for this indication.